Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 6.7%

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shot up 6.7% on Friday . The stock traded as high as $24.53 and last traded at $24.53. 11,869 shares traded hands during trading, a decline of 98% from the average session volume of 518,577 shares. The stock had previously closed at $22.98.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ARCT shares. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a report on Tuesday, July 2nd. Canaccord Genuity Group dropped their target price on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Finally, William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.60.

Arcturus Therapeutics Stock Up 4.9 %

The business’s 50-day moving average is $28.46 and its 200-day moving average is $31.54. The company has a market capitalization of $649.01 million, a price-to-earnings ratio of -6.27 and a beta of 2.64.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.17) by $0.17. The business had revenue of $38.01 million during the quarter, compared to analysts’ expectations of $22.12 million. Arcturus Therapeutics had a negative return on equity of 37.61% and a negative net margin of 81.59%. As a group, analysts expect that Arcturus Therapeutics Holdings Inc. will post -4.39 EPS for the current year.

Insider Activity at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 26,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the sale, the chief operating officer now directly owns 447,448 shares in the company, valued at approximately $17,902,394.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 13.80% of the company’s stock.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds have recently made changes to their positions in ARCT. Wellington Management Group LLP raised its stake in Arcturus Therapeutics by 2.6% in the 3rd quarter. Wellington Management Group LLP now owns 43,350 shares of the biotechnology company’s stock valued at $1,108,000 after purchasing an additional 1,098 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Arcturus Therapeutics by 352.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 2,406 shares during the last quarter. Arizona State Retirement System purchased a new position in shares of Arcturus Therapeutics in the fourth quarter worth about $211,000. Tritonpoint Wealth LLC acquired a new position in Arcturus Therapeutics during the fourth quarter worth about $885,000. Finally, DekaBank Deutsche Girozentrale grew its stake in Arcturus Therapeutics by 3.0% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 43,889 shares of the biotechnology company’s stock valued at $1,401,000 after acquiring an additional 1,272 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.